Objective:In the present study, neuronal PC12 cells and hippocampal HT22 cells maintained in culture were used to test the neuroprotective effect of equine estrogens estrone, 17β-estradiol, 17α-estradiol, equlin, 17β-dihydroequilin, 17α-dihydroequilin, equilenin, 17β-dihydroequilenin, 17α-dihydroequilenin, Δ8-estrone and Δ8,17β-estradiol against glutamate toxicity.
Methods:The HT22 and PC12 cells were grown in Dulbecco modified Eagle medium supplemented with 5% horse serum, 10% fetal bovine serum,and 10 mM HEPES. The undifferentiated PC12 cells were plated on collagen-coated, 96-well plastic plates at 10,000 cells per well, and the HT22 cells were plated on uncoated 96-well plates at 2500 cells per well. Twenty-four hours after plating, various concentrations of estrogens (0.1-40 μM) and glutamate (1-10 mM) were added in a total volume of 100 μL. After 24 hours, cell viability was determined using the MTS cell proliferation assay. Reslts were verified in some experiments by using the lactate dehydrogenase cytotoxicity assay.
Results:The results indicate that cell toxicity in both cell lines was directly proportional to the concentration of glutamate. The lowest dose of glutamate that reduced cell viability by 50% under these conditions was 1.8 mM for HT22 cells and 3 mM for PC12 cells. All estrogens tested were neuroprotective against glutanate-induced cell death in a typical dose-related manner. However, these estrogens differed extensively with respect to their neuroprotective potencies. In both cell lines, the Δ8-ring B unsaturated estrogens were the most neuroprotective, whereas the classic estrogens 17β-estradiol, estrone, and 17α-estradiol were the least potent. The order of potency was Δ8,17β-estradiol > Δ8-estrone > 17β-dihydroequilenin > 17α-dihydroequilenin > equilenin > 17β-dihydroequilin = equilin > 17α-dihydroequilin > 17β-estradiol > estrone > 17α-estradiol in PC12 cells and Δ7,17β-estradiol > Δ8-estrone > equilenin = 17β-dihydroequilenin > 17β-dihydroequilin > equilin > 17α-dihydroequilenin > 17α-dihydroequilin > 17α-estradiol = 17β-estradiol > estrone in HT22 cells.
Conclusion:Our data indicate that the neutrotoxic effects of glutamate can be inhibited differentially by various equine estrogens. The less estrogenic (uterotropic) Δ8 estrogens were the most effective neuroprotectors, and further chemical modifications of these estrogens may provide compounds that are useful for preventing neurodegenerative diseases in both women and men.
1. Fonnun F. Glutamate: A neurotransmitter in mammalian brain. J Neurochem1984;42:1-11.
2.
2. Coyle JT, Puttfracken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science1993;262:689-695.
3.
3. Choi DW. Glutamate receptors and the induction of excitotoxic neuronal death. Progr Brain Res1994;100:47-51.
4.
4. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurological disorders. N Engl J Med1994;330:613-622.
5.
5. Froissard P, Duval D. Cytotoxic effects of glutamic acid on PC12 cells. Neurochem INt1994;24:485-493.
6.
6. Davis JB, Maher P. Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line. Brain Res1994;652:169-173.
7.
7. Behl C, Widmann M, Trapp J. Holsboer F. 17β-estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun1995;216:473-482.
8.
8. Lezoualch F, Skutella T, Widmann M, Behl C. Melatonin prevents oxidative stress-induced cell death in hippocampal cells. Neuro Rep1996;2071-2077.
9.
9. Tyurin VA, Tyurina YY, Quinn PJ, et al. Glutamate-induced cytotoxicity in PC12 pheochroma cytoma cells: Role of oxidation of phospholipids, glutathione and protein sulfhydryls revealed by bcl-2 transfection. Brain Res Mol Brain Res1998;60:270-281.
10.
10. Zanlyanov LL, Green PS, Simpkins JW. Glutamate receptor requirement for neuronal death from anoxia-reoxygenation: An in vitro model for assessment of the neuroprotective effects of estrogens. Cell Mol Neurobiol1999;19:765-818.
11.
11. Nicotera P, Ankarcrona M, Bonjoco E, Orrenius S, Lipton SA. Neuronal necrosis and apoptosis: Two distinct events induced by exposure to glutamate or oxidative stress. Adv Neurol1997;72:95-101.
12.
12. Subiah MT, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski Z. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab1993;77:1095-1097.
13.
13. Wilcox JY, Hwang J, Hodis HN, Sevanian A, Lobo RA. Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low density lipoproteins. Fertil Steril1997;64:57-62.
14.
14. Bhavnani BR, Cecutti A, Gerulath A, Woolever AC. Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and propucol on low-density lipoprotein oxidation in postmenopausal women. Menopause2001;8:408-419.
15.
15. Berco M, Bhavnani BR. Differential neuroprotective effects of equine estrogens against oxidized low density lipoprotein-induced neuronal cell death. J Soc Gynecol Investig2001;8:245-254.
16.
16. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell1994;77:817-827.
17.
17. Slivka A, Cohen G. Hydroxyl radical attack on dopamine. J Biol Chem1985;260:15466-15472.
18.
18. Pagahini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease. Am J Epidemiol1994;140:251-256.
19.
19. Henderson VW. The epidemilogy of estrogen replacement therapy and Alzheimer's disease. Neurology1997;48(Suppl):S27-S35.
20.
20. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet1996;348:429-432.
21.
21. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Logitudinal Study of Aging. Neurology1997;48:1517-1521.
22.
22. Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: Chemistry and metabolism, Proc Soc Exp Biol Med1998;217:6-16.
23.
23. Bhavnani BR, Cecutti A, Gerulath A. Pharmacokinetics and pharmacodynamics of a novel estrogen delta-8-estrone in postmenopausal women and men. J Steroid Biochem Mol Biol1998;67:119-131.
24.
24. Greene LA, Tischler AS. Establishment of noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A1976;73:2424-2428.
25.
25. Greene PS, Gordon D, Simpkins JW. Phenolic A ring requirement for the the neuroprotective effect of steroids. J Steroid Biochem Mol Bil1997;63:229-235.
26.
26. Moosmann B, Behl C. The antioxidant neutroprotective effect of estrogens and phenolic compounds are independent from their estrogenic properties. Proc Natl Acad Sci U S A1999;96:8867-8872.
27.
27. Behl C, Skutella T, Lezoual CF, Pot A, Widmann M, Newton CJ. Neuroprotection against oxidative stress by estrogens: Structure-activity relationship. Mol Pharmacol1997;51:535-541.
28.
28. Green PS, Gridley KE, Simpkins JW. Nuclear estrogen receptor-independent neuroprotection by estratrienes. A novel interaction with glutathione. Lett Neurosci1998;84:7-10.
29.
29. Bhavnani BR, Nisker JA, Martin J, Alelebi F, Watson L, Milne JK. Comparison of pharmacokinetics of a conjugated equine estrogen preparation (Premarin) and a synthetic mixture of estrogens (C:E.S) in postmenopausal women. J Soc Gynecol Investig2000;7:175-183.
30.
30. Behl C. Vitamin E and other antioxidants in neuroprotection. Int J Vitam Nutr Res1999;69:213-219.
31.
31. Chen J, Adachi N, Liu K, Arai T. The effect of 17β-estradiol on ischemia-induced neuronal damage in the gerbil hippocampus. Neuroscience1998;87:817-822.
32.
32. Nilsen J, Mor G, Naftolin F. Raloxifen induces neurite outgrowth in estrogen receptor positive cells PC12 cells. Menopause1998;5:211-216.
33.
33. Gursoy E, Cardounel A, Al-Khlaiwi A, Al-dress A, Kalimi M. Tamoxifen protects clonal mouse hippocampal (HT22) cells against neurotoxin-induced cell death. Neurochem Int2002:40:405-412.
34.
34. Nakajima T, Kitazawa T, Hamada E. 17β-estradiol inhibits the voltage dependent L-type Ca2+ currents in aortic smooth muscle cells. Eur J Pharmacol1995;294:625-635.
35.
35. Mermelstein PY. Becker JB, Surmeier DJ, Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J Neurosci1996;16:595-604.
36.
36. Woolley C. McEwen BS. Estradiol regulates hippocampal dentritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci1994;14:7580-7687.
37.
37. O'Malley CA, Hantamaki RD, Kelley M, Meyer EM. Effects of ovariectomy and estradiol benzoate on high affinity choline uptake, A Ch synthesis, and release from rat cerebral cortical synaptosomes. Brain Res1987;403:389-392.
38.
38. Pentitti N, Karkanial G, Etgen AM. Estradiol selectively regulates alpha1β-noradrenergic receptors in the hypothalamus and preoptic area. J Neurosci1992;12:3869-3876.
39.
39. Panikark S, Guan G, King MA, Rajakumar G, Simpkins JW. 17β-estradiol attenuates CREB decline in rat hippocampus following seizure. J Neurobiol1997;33:961-967.
40.
40. Auer RN, Kalimo H, Olsson Y, Siesjo BJ. The temporal evolution of hypoglycemic brain damage. II. Light and electromicroscopic findings in the hippocampal gyrus and subiculum of the rat. Acta Neuropathol1985;67:25-36.
41.
41. Singh M, Meye EM, Simpkins JW. The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of the female Sprague-Dawley rats. Endocrinology1995;136:2320-2324.
